Martin MacKay is VP at ALEXION PHARMACEUTICALS INC (ALXN). They have made 14 open-market trades across 2 companies since 2014, most recently 2026-05-08.
CIK 0001414815
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $159K since 2022, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RLYB | BUY | 2022-01-10 | 2022-01-12 | $10.26 | $159K | -6.6% | +38.5% | -20.5% |
| ALXN | SELL | 2017-02-27 | 2017-03-01 | $131.53 | $439K | -6.7% | -9.4% | -26.9% |
| ALXN | SELL | 2017-02-09 | 2017-02-10 | $126.84 | $28K | +2.5% | -1.9% | -6.4% |
| ALXN | SELL | 2017-02-06 | 2017-02-08 | $125.69 | $684K | +2.4% | +0.4% | -1.7% |
| ALXN | SELL | 2016-05-16 | 2016-05-18 | $139.19 | $1.1M | +7.1% | -11.1% | -5.1% |
| ALXN | SELL | 2016-02-29 | 2016-03-01 | $138.91 | $139K | -6.9% | -6.9% | +0.9% |
| ALXN | SELL | 2016-02-05 | 2016-02-08 | $139.76 | $1.0M | +6.5% | +2.6% | +4.8% |
| ALXN | SELL | 2015-08-03 | 2015-08-05 | $196.52 | $8.5M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2015-05-14 | 2015-05-22 | $160.33 | $650K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2015-03-02 | 2015-03-03 | $180.34 | $67K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2015-02-10 | 2015-02-12 | $173.97 | $678K | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2014-11-03 | 2014-11-04 | $191.52 | $1.8M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2014-06-12 | 2014-06-13 | $166.42 | $4.2M | -15.6% | -1.2% | -1.2% |
| ALXN | SELL | 2014-05-14 | 2014-05-15 | $160.85 | $575K | -15.6% | -1.2% | -1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.